|
JPS58216123A
(ja)
|
1982-06-10 |
1983-12-15 |
Kazue Ueno |
抗血清
|
|
US4530833A
(en)
*
|
1982-09-13 |
1985-07-23 |
Wilkins Tracy D |
Toxins and antibodies of C. difficile
|
|
US4689299A
(en)
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
|
EP0154064A1
(en)
*
|
1984-03-02 |
1985-09-11 |
Tracy Dale Wilkins |
Toxins and antibodies of C. difficile
|
|
US4713240A
(en)
|
1985-04-04 |
1987-12-15 |
Research Corporation |
Vaccines based on insoluble supports
|
|
US5358868A
(en)
|
1987-11-24 |
1994-10-25 |
Connaught Laboratories Limited |
Genetic detoxification of pertussis toxin
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5919665A
(en)
|
1989-10-31 |
1999-07-06 |
Ophidian Pharmaceuticals, Inc. |
Vaccine for clostridium botulinum neurotoxin
|
|
US5599539A
(en)
|
1989-10-31 |
1997-02-04 |
Ophidian Pharmaceuticals, Inc. |
Therapy for clostridial botulinum toxin
|
|
US5601823A
(en)
|
1989-10-31 |
1997-02-11 |
Ophidian Pharmaceuticals, Inc. |
Avian antitoxins to clostridium difficle toxin A
|
|
US5578308A
(en)
|
1990-02-12 |
1996-11-26 |
Capiau; Carine |
Glutaraldehyde and formalin detoxified bordetella toxin vaccine
|
|
US5231003A
(en)
|
1990-05-11 |
1993-07-27 |
Cambridge Bioscience Corporation |
Monoclonal antibodies specific for toxin b of clostridium difficile
|
|
JPH06509866A
(ja)
|
1991-04-22 |
1994-11-02 |
マサチューセッツ ヘルス リサーチ インスティチュート，インコーポレーテッド |
呼吸系ウイルスに対する有効な抗体力価用の血漿試料をスクリーニングする方法
|
|
US6221363B1
(en)
|
1991-07-11 |
2001-04-24 |
Baxter Aktiengesellschaft |
Vaccine for the prevention of lyme disease
|
|
AU689772B2
(en)
|
1993-03-29 |
1998-04-09 |
Zoetis Llc |
Multicomponent clostridial vaccines using saponin adjuvants
|
|
AU702405B2
(en)
|
1994-09-06 |
1999-02-18 |
Immucell Corporation |
Therapeutic treatment of clostridium difficile associated diseases
|
|
DE69535530D1
(de)
|
1994-10-24 |
2007-08-16 |
Ophidian Pharm Inc |
Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
|
|
US6743430B1
(en)
|
1995-03-29 |
2004-06-01 |
Richard E. Parizek |
Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
|
|
US5610023A
(en)
|
1995-03-31 |
1997-03-11 |
Lee Laboratories, Inc. |
Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
|
|
ATE195878T1
(de)
|
1995-07-07 |
2000-09-15 |
Oravax Inc |
Toxine und toxoide von clostridium difficile als schleimhautadjuvans
|
|
US5919463A
(en)
|
1995-07-07 |
1999-07-06 |
Oravax, Inc. |
Clostridium difficle toxins as mucosal adjuvants
|
|
CA2226392A1
(en)
|
1995-07-07 |
1997-01-30 |
James S. Moncrief |
Intranasal vaccination against gastrointestinal disease
|
|
DE69635496T2
(de)
|
1995-09-15 |
2006-07-27 |
Gerding, Dale N., Chicago |
Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
|
|
KR100382224B1
(ko)
|
1996-09-30 |
2003-04-26 |
엠브렉스, 인코포레이티드 |
백신 컨쥬게이트를 이용한 능동면역 생성방법
|
|
US20100267012A1
(en)
|
1997-11-04 |
2010-10-21 |
Bergeron Michel G |
Highly conserved genes and their use to generate probes and primers for detection of microorganisms
|
|
EP1005368B1
(en)
|
1997-03-10 |
2009-09-02 |
Ottawa Hospital Research Institute |
Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
|
|
US6299881B1
(en)
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
|
US20050106157A1
(en)
|
1997-05-27 |
2005-05-19 |
Deckers Harm M. |
Immunogenic formulations comprising oil bodies
|
|
AU746859B2
(en)
|
1997-06-20 |
2002-05-02 |
Imperial College Of Science, Technology And Medicine |
Immonogenic fragments of toxin a of clostridium difficile
|
|
DE19739685A1
(de)
|
1997-09-10 |
1999-03-11 |
Eichel Streiber Christoph Von |
Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
|
|
EP1568378B1
(en)
|
1997-10-20 |
2016-03-16 |
Sanofi Pasteur Biologics, LLC |
Immunization against Clostridium difficile disease
|
|
DE69829400T2
(de)
|
1997-10-20 |
2006-04-13 |
Acambis, Inc., Cambridge |
Passive immunisierung gegen durch clostridium difficile verursachte krankheit
|
|
US6969520B2
(en)
|
1997-10-20 |
2005-11-29 |
Acambis Inc. |
Active immunization against clostridium difficile disease
|
|
US6733760B1
(en)
|
1999-04-09 |
2004-05-11 |
Techlab, Inc. |
Recombinant toxin A/toxin B vaccine against Clostridium difficile
|
|
JP2002541808A
(ja)
|
1999-04-09 |
2002-12-10 |
テクラブ， インコーポレイテッド |
ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
|
|
WO2000061762A1
(en)
|
1999-04-09 |
2000-10-19 |
Techlab, Inc. |
RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
|
|
TR200103018T2
(tr)
|
1999-04-19 |
2002-02-21 |
Beecham Biologicals S.A. Smithkline |
İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
|
|
GB0008682D0
(en)
|
2000-04-07 |
2000-05-31 |
Microbiological Res Authority |
Transformation of clostridium difficile
|
|
CZ20023662A3
(cs)
|
2000-05-04 |
2003-04-16 |
President And Fellows Of Harvard College |
Sloučeniny a způsoby léčení a prevence bakteriální infekce
|
|
ES2279869T3
(es)
|
2001-06-20 |
2007-09-01 |
Ramot At Tel Aviv University Ltd. |
Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
|
|
US20040029129A1
(en)
|
2001-10-25 |
2004-02-12 |
Liangsu Wang |
Identification of essential genes in microorganisms
|
|
AU2003242024A1
(en)
|
2002-06-05 |
2003-12-22 |
Chugai Seiyaku Kabushiki Kaisha |
Method of constructing antibody
|
|
AU2003299527A1
(en)
|
2002-06-17 |
2004-06-07 |
Jimmy D. Ballard |
Mutant of clostridium difficile toxin b and methods of use
|
|
US20040235139A1
(en)
*
|
2002-12-23 |
2004-11-25 |
Demain Arnold L. |
Clostridium difficile culture and toxin production methods
|
|
US20050020506A1
(en)
|
2003-07-25 |
2005-01-27 |
Drapeau Susan J. |
Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
|
|
AU2005206951B2
(en)
|
2004-01-16 |
2010-08-19 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
NZ530709A
(en)
*
|
2004-01-21 |
2006-07-28 |
Agres Ltd |
Improved IGA production method
|
|
DK1766093T3
(da)
*
|
2004-02-06 |
2011-10-03 |
Univ Massachusetts |
Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
|
|
EP1833510A4
(en)
|
2004-12-27 |
2010-02-10 |
Progenics Pharmaceuticals Neva |
ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
|
|
CN1930186A
(zh)
*
|
2005-03-03 |
2007-03-14 |
阿勒根公司 |
为获得梭菌毒素的梭菌细菌培养基及方法
|
|
WO2006130925A1
(en)
|
2005-06-10 |
2006-12-14 |
Monash University |
Genetic manipulation of clostridium difficile
|
|
GB0512751D0
(en)
*
|
2005-06-22 |
2005-07-27 |
Glaxo Group Ltd |
New adjuvant
|
|
EP1987361A4
(en)
|
2006-01-30 |
2009-03-04 |
Invitrogen Corp |
COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
|
|
GB0612301D0
(en)
|
2006-06-21 |
2006-08-02 |
Morvus Technology Ltd |
DNA molecules and methods
|
|
US20080206819A1
(en)
|
2006-08-21 |
2008-08-28 |
Mary Tsao |
Intensified Perfusion Production Method
|
|
SI2124556T1
(sl)
*
|
2006-10-09 |
2015-01-30 |
Charleston Laboratories, Inc. |
Farmacevtske sestave
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
EP2014760A1
(en)
|
2007-06-13 |
2009-01-14 |
CMC Biopharmaceuticals A/S |
A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
|
|
US9096638B2
(en)
|
2007-09-06 |
2015-08-04 |
Geneohm Sciences Canada, Inc. |
Detection of toxigenic strains of Clostridium difficile
|
|
WO2009035707A1
(en)
|
2007-09-14 |
2009-03-19 |
Acambis Inc. |
Pharmaceutical compositions containing clostridium difficile toxoids a and b
|
|
WO2009132082A2
(en)
|
2008-04-22 |
2009-10-29 |
Medical College Of Georgia Research Institute, Inc. |
Immunogenic compositions containing ceramide and methods of use thereof
|
|
EP2288719A4
(en)
|
2008-05-15 |
2012-01-11 |
Univ Tufts |
METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION
|
|
WO2009156852A1
(en)
|
2008-06-25 |
2009-12-30 |
Novartis Ag |
Rapid responses to delayed booster immunisations
|
|
EP2146490A1
(en)
|
2008-07-18 |
2010-01-20 |
Alcatel, Lucent |
User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
|
|
CA2733425A1
(en)
*
|
2008-08-06 |
2010-02-11 |
Emergent Product Development Uk Limited |
Vaccines against clostridium difficile and methods of use
|
|
EP2329029B1
(en)
|
2008-09-24 |
2016-06-08 |
Sanofi Pasteur Biologics, LLC |
Methods and compositions for increasing toxin production
|
|
EP2346523A4
(en)
*
|
2008-10-01 |
2014-12-31 |
Us Health |
MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
|
|
US10369204B2
(en)
|
2008-10-02 |
2019-08-06 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
|
JP2012510497A
(ja)
|
2008-12-03 |
2012-05-10 |
ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ワクチンの生産方法
|
|
CA2745096C
(en)
|
2008-12-09 |
2013-11-05 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
|
GB0901001D0
(en)
|
2009-01-22 |
2009-03-04 |
Univ Nottingham |
Methods
|
|
WO2010094970A1
(en)
|
2009-02-20 |
2010-08-26 |
Health Protection Agency |
Antibodies to clostridium difficile toxins
|
|
US8420352B2
(en)
|
2009-08-27 |
2013-04-16 |
Synaptic Research, Llc |
Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
|
|
WO2011060431A2
(en)
|
2009-11-16 |
2011-05-19 |
University Of Maryland Baltimore |
Multivalent live vector vaccine against clostridium difficile-associated disease
|
|
EP2519257A4
(en)
|
2009-12-02 |
2014-10-15 |
Univ Tufts |
ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
|
|
GB0921288D0
(en)
|
2009-12-04 |
2010-01-20 |
Health Prot Agency |
Therapies for preventing or suppressing clostridium difficile infection
|
|
TW201136603A
(en)
|
2010-02-09 |
2011-11-01 |
Merck Sharp & Amp Dohme Corp |
15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
|
|
BR112012024898A2
(pt)
*
|
2010-03-30 |
2015-10-06 |
Pfenex Inc |
expressão de nível elevado de proteínas recombinantes de toxinas
|
|
US8765399B2
(en)
*
|
2010-05-18 |
2014-07-01 |
Montefiore Medical Center |
Cultures and protocols for diagnosis of toxigenic Clostridium difficile
|
|
WO2012028418A1
(en)
*
|
2010-09-02 |
2012-03-08 |
Novacem Limited |
Integrated process for producing compositions containing magnesium
|
|
EP3167899B1
(en)
|
2010-09-03 |
2021-03-24 |
Valneva Austria GmbH |
Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
|
|
GB201016742D0
(en)
|
2010-10-05 |
2010-11-17 |
Health Prot Agency |
Clostridium difficile antigens
|
|
WO2012078313A2
(en)
|
2010-11-12 |
2012-06-14 |
Reflexion Pharmaceuticals, Inc. |
Gb1 peptidic libraries and compounds, and methods of screening the same
|
|
CN102533867A
(zh)
*
|
2010-12-10 |
2012-07-04 |
西北民族大学 |
一种艰难梭菌a毒素的类毒素的制备方法
|
|
MX391236B
(es)
*
|
2011-04-22 |
2025-03-21 |
Wyeth Llc |
Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
|
|
EP3564378B1
(en)
*
|
2011-05-27 |
2023-11-01 |
GlaxoSmithKline Biologicals SA |
Immunogenic composition
|
|
US9770500B2
(en)
|
2011-05-31 |
2017-09-26 |
The Board Of Regents Of The University Of Texas System |
S-nitrosylation of glucosylating toxins and uses therefor
|
|
WO2013082298A2
(en)
*
|
2011-11-30 |
2013-06-06 |
Board Of Trustees Of Michigan State University |
Immunological composition for clostridium difficile
|
|
SG11201402375VA
(en)
|
2011-12-08 |
2014-10-30 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
|
AR089797A1
(es)
|
2012-01-27 |
2014-09-17 |
Merck Sharp & Dohme |
Vacunas contra clostridum difficile que comprenden toxinas recombinantes
|
|
BR112015004629A2
(pt)
*
|
2012-09-19 |
2017-11-21 |
Novartis Ag |
polipeptídeos de clostridium difficile como vacinas
|
|
BR122016023101B1
(pt)
*
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
|
JP2016501877A
(ja)
*
|
2012-11-28 |
2016-01-21 |
シーエヌジェー ホールディングス，インコーポレイテッド |
クロストリジウム・ディフィシルに対する抗体
|
|
AU2013354186A1
(en)
*
|
2012-12-05 |
2014-06-12 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
|
GB201223342D0
(en)
*
|
2012-12-23 |
2013-02-06 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
US20160045586A1
(en)
*
|
2013-03-15 |
2016-02-18 |
Sanofi Pasteur, Inc. |
Toxoid, Compositions and Related Methods
|
|
EP4079760A3
(en)
*
|
2013-03-15 |
2023-01-25 |
Sanofi Pasteur Inc. |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
EP2981611A4
(en)
|
2013-04-02 |
2016-11-16 |
Stc Unm |
ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
|
|
SG11201510166YA
(en)
|
2013-06-14 |
2016-01-28 |
Sanofi Pasteur Inc |
Compositions and methods of immunizing against c. difficile
|
|
US20160250283A1
(en)
*
|
2013-10-23 |
2016-09-01 |
The Rockefeller University |
Compositions and methods for prophylaxis and therapy of clostridium difficile infection
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
HK1259103A1
(zh)
|
2015-11-17 |
2019-11-22 |
Pfizer Inc. |
用於在细菌细胞培养物中生产多糖的培养基和发酵方法
|
|
MA44252A
(fr)
*
|
2016-02-16 |
2018-12-26 |
Harvard College |
Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
|
|
AU2018236352B2
(en)
|
2017-03-15 |
2024-04-04 |
Novavax, Inc. |
Methods and compositions for inducing immune responses against clostridium difficile
|
|
CA3016351A1
(en)
|
2017-09-05 |
2019-03-05 |
Mcmaster University |
Aptamers for clostridium difficile detection
|
|
CA3076961A1
(en)
|
2017-09-28 |
2019-04-04 |
Pfizer Inc. |
Compositions and methods for eliciting an immune response against clostridium difficile
|
|
US20220160859A1
(en)
|
2019-04-01 |
2022-05-26 |
Pfizer Inc. |
Compositions and methods for eliciting an immune response against clostridium difficile
|
|
US20230218735A1
(en)
|
2020-06-19 |
2023-07-13 |
Pfizer Inc. |
Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
|